On Demand 2018 Thursday Program

The Thursday Program contains the morning and afternoon sessions:

  • Biologic Therapies in Your Practice
    • Phenotypes/Endotypes for Biologics
    • Targets in Use of Biologics
    • Asthma and Upper Airway Diseases
    • Dermatologic Diseases (using biologics)
    • How to Choose, Use and Bill
  • Drug Allergy and the Allergist: Staying Relevant
    • Antibiotic Desensitization
    • Antiobiotic Stewardship
    • The Allergist in the Community Hospital
    • How Academic Centers are Reacting
    • Drug Allergy Coding and Billing

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 6 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Outline an approach to the use of biologics for allergic diseases.
  • Describe clinical criteria for severe asthma and allergic diseases and identify known phenotypes and endotypes that can inform treatment selection.
  • Utilize available information to guide personalized treatment of asthma and allergic diseases and describe the most recent clinical data on new and emerging therapies.
  • Utilize available information to guide personalized treatment of atopic dermatitis and chronic urticaria and describe the most recent clinical data on new and emerging therapies.
  • Develop an understanding on how to effectively choose, use and bill for biologics.
  • Summarize and plan how to utilize antibiotic desensitization.
  • Recognize how antibiotic stewardship works and identify the allergist’s role.
  • Give examples of how the allergist can assist in various settings with drug allergies.
  • Distinguish the different coding and billing options available for drug allergy evaluation and testing.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (College) policy, the College must identify and resolve conflicts of interest for all individuals responsible for the development, management, presentation, or evaluation of content for a CME activity. Financial disclosures are reviewed in advance, to ensure any potential conflicts of interest are resolved. Disclosure in no way implies that the information presented is biased or of lesser quality; it is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Specific disclosure information for the 2018 Annual Meeting is now available online.

Course summary
Available credit: 
  • 6.00 AMA PRA Category 1 Credit™
  • 6.00 Attendance
Course opens: 
12/01/2018
Course expires: 
11/30/2021
Rating: 
0

Larry Borish, MD, FACAAI

Tara Carr, MD

Thomas Casale, MD

Mariana Castells, MD, PhD, FACAAI

Jonathan Corren, MD

Emma Guttman-Yassky, MD

David Khan, MD,  FACAAI

David Lang, MD, FACAAI

Bobby Lanier, MD

Eric Macy, MD

Santiago Martinez, MD, FACAAI

John Oppenheimer, MD, FACAAI

Stephen Peters, MD, PhD

Jonathan Silverberg, MD, PhD, MPH

David Spach, MD

James L. Sublett, MD, FACAAI

Michael Weiss, MD

Cherie Zachary, MD, FACAAI

Available Credit

  • 6.00 AMA PRA Category 1 Credit™
  • 6.00 Attendance
Please login or create an account to take this course.